Trial · NCT02659020
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase 1b: Cohort 1 - 15 mg/kg Olaratumab + Gemcitabine + Docetaxel | 21 | |
| Overall Study | STARTED | Phase 1b: Cohort 2 - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel | 18 | |
| Overall Study | STARTED | Phase 1b: Cohort 2 Expansion - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel | 15 | |
| Overall Study | STARTED | Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab-naive) | 81 | |
| Overall Study | STARTED | Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab Pre-treated) | 46 | |
| Overall Study | STARTED | Phase 2: Placebo + Gemcitabine + Docetaxel (Olaratumab-naive) | 86 | |
| Overall Study | STARTED | Phase 2: Placebo + Gemcitabine + Docetaxel (Olaratumab Pre-treated) | 43 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase 1b: Cohort 1 - 15 mg/kg Olaratumab + Gemcitabine + Docetaxel | 21 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase 1b: Cohort 2 - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel | 18 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase 1b: Cohort 2 Expansion - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel | 15 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab-naive) | 81 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab Pre-treated) | 45 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase 2: Placebo + Gemcitabine + Docetaxel (Olaratumab-naive) | 86 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Phase 2: Placebo + Gemcitabine + Docetaxel (Olaratumab Pre-treated) | 43 | |
| Overall Study | COMPLETED | Phase 1b: Cohort 1 - 15 mg/kg Olaratumab + Gemcitabine + Docetaxel | 18 | |
| Overall Study | COMPLETED | Phase 1b: Cohort 2 - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel | 15 | |
| Overall Study | COMPLETED | Phase 1b: Cohort 2 Expansion - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel | 14 | |
| Overall Study | COMPLETED | Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab-naive) | 65 | |
| Overall Study | COMPLETED | Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab Pre-treated) | 40 | |
| Overall Study | COMPLETED | Phase 2: Placebo + Gemcitabine + Docetaxel (Olaratumab-naive) | 75 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02659020/flow